摘要:目的:探討良性前列腺增生經尿道前列腺電切術圍手術期的護理經驗。方法:回顧性分析96例良性前列腺增生患者臨床資料。結果:96例患者手術順利,圍手術期經周密的護理,療效滿意,無明顯并發癥。結論:周密的手術期護理對經尿道前列腺電切術治療老年良性前列腺增生十分重要。Abstract: Objective: To investigate the perioperative nursing care of transurethral prostatic resection (TURP). Methods: The data of 96 TURP cases were analyzed retrospectively. Results: All the operations were performed successfully, and there were no obvious complications among the patients with precise nursing care. Conclusion: It is very important for precise nursing care to the patients who underwent TURP.
摘要:目的:探討經尿道前列腺等離子切除術(PKRP)治療前列腺增生癥(BPH)的療效及安全性。方法:回顧分析采用PKRP治療的BPH患者,收集患者臨床資料,隨訪12個月,并對手術前后患者國際前列腺癥狀評分、最大尿流率、生活質量評分進行比較。結果:2006年8月至2008年8月PKRP手術治療BPH患者共238例,手術時間30～159 min,平均70 min,切除腺體25～127 g,平均54 g。無電切綜合征。術后及1年后最大尿流率、國際前列腺癥狀評分、生活質量評分三項指標較術前明顯改善(Plt;0.05)。結論:PKRP是治療BPH安全有效的治療方式。Abstract: Objective: To assess the clinical efficacy and safety of plasmakinetic energy transurethral resection of the prostate (PKRP) for benign prostatic hypertrophy (BPH). Methods: The data of patients with BPH treated with PKRP were retrospectively analyzed and the International Prostate Symptoms Scales (IPSS), maximum flow rate (Qmax) and Quality of Life (QOL) of patients with 12month followup were compared before and afteroperation and postoperation. Results: A total of 238 patients with BPH were enrolled from June 2006 to June 2008. The duration of the procedure was 70. 3 min (ranged from 30 min to 159 min) and the weight of dissected tissue was 54 g (ranged from 25 g to 127 g). No transurethral resection syndrome occurred. IPSS, Qmax and QOL were improved obviously after operation (Plt;0.05). Conclusion: PKRP is effective and safe.
【摘要】 目的 評價非那雄胺對良性前列腺增生（benign prostate hyperplasia，BPH）細胞外基質（extracellular matrixc，ECM）的影響，并探討其作用機制。 方法 2008年6月－2009年3月選擇具備手術指征的BPH患者20例，按入院順序隨機分為非那雄胺組和安慰劑組。服藥4周后，行經尿道前列腺切除術（transurethral resection prostate，TURP），留取組織標本。另取正常前列腺標本6例，用免疫組織化學法結合圖像分析系統研究正常組、安慰劑組和非那雄胺組前列腺組織纖維連接蛋白（FN）、膠原（CL）、基質金屬蛋白酶2（MMP-2）、金屬蛋白酶組織抑制因子2（TIMP-2）的陽性表達。 結果 安慰劑組前列腺組織的FN、CL的陽性表達較正常組增強（Plt;0.01），MMP-2/TIMP-2差異無統計學意義（Pgt;0.05）；非那雄胺組與安慰劑組相比，FN、CL的陽性表達減弱（Plt;0.01），而MMP-2/TIMP-2增高（Plt;0.01）。 結論 非那雄胺能降低BPH組織ECM成分，避免其沉積，其作用機制可能與其促進ECM降解有關。【Abstract】 Objective To evaluate influence of finasteride on extracellular matrix (ECM) in benign prostate hyperplasia (BPH) patients and study the mechanism. Methods Twenty BPH patients needing surgery were randomly divided into 2 groups according to the sequence of hospitalization from June 2008 to March 2009. The finasteride group and the placebo group had 10 patients each. Transurethral resection prostate (TURP) were performed and the specimens were collected after 4 weeks of drug administration. Moreover, 6 normal prostatic tissues were selected. Expressions of fibronectin (FN), collagen (CL), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) were studied in prostatic tissues in all groups (including the normal group) by immunohistochemistry and image analysis system. Results Expressions of FN and CL were significantly higher than those in the normal group (Plt;0.01), while expressions of MMP-2 and TIMP-2 were not significantly different between them (Pgt;0.05). Compared with the placebo group, expressions of FN and CL in the finateride group were significantly lower than the placebo group (Plt;0.01), while expressions of MMP-2 and TIMP-2 were significantly higher (Plt;0.01). Conclusions BPH is related to ECM depositing. Finasteride can decrease ECM of BPH and refrain it from depositing. Possibly, the principle is that finasteride can promote the degradation of ECM.
【摘要】 目的 探討良性前列腺增生（benign prostatic hyperplasia，BPH）伴膀胱結石的有效腔內治療方法。〖HTH〗方法 2003年6月-2009年12月，使用F26號電切鏡外鞘作為撐開器，氣壓彈道和（或）鈥激光粉碎膀胱結石，經尿道前列腺電切術 （transurethral resection of the prostate，TURP） 治療BPH伴膀胱結石86例。患者年齡58～83歲，平均68.6歲；病程2～8年，平均5.2年。術前患者國際前列腺癥狀評分（international prostate symptom score，IPSS）為（24.6±3.9）分，生活質量（5.7±0.6）分；前列腺重量（46.5±6.8） g，剩余尿量（185±58） mL，最大尿流率（5.7±2.3） mL/s。 結果 86例均一次手術成功。碎石時間為16~58 min，平均38 min；前列腺電切時間40~100 min，平均65 min。術中無并發癥發生。術后 5~8 d拔除尿管，平均6.5 d。術后4 例出現前尿道狹窄，經治療后痊愈。54例獲隨訪，隨訪時間2~6個月，平均3個月。術后2個月，54例最大尿流率升至（18.5±4.1） mL/s，剩余尿量下降至（16±22） mL，IPSS評分下降至（7.8±1.6）分，生活質量（2.5±0.3）分，與術前比較差異均有統計學意義（Plt;0.01）。 結論 經尿道碎石術和TURP一次性治療BPH伴膀胱結石安全、有效、經濟。【Abstract】 Objective To explore an effective endourologic treatment method for benign prostatic hyperplasia (BPH) with bladder calculi. Methods From June 2003 to December 2009, ballistic or holmium laser lithotripsy by outer sheath resectoscope and transurethral resection of the prostate (TURP) were performed on 86 patients with BPH and bladder calculi. The patients aged 58 to 83 years old, averaging at 68.6 years. Duration of their disease course ranged from 2 to 8 years, averaging 5.2 years. Before surgery, the international prostate symptom score (IPSS) was 24.6±3.9; the score of quality of life (QOL) was 5.7±0.6; prostatic weight was (46.5±6.8) g; residual urine (RU) volume was (185±58) mL; and the peak urine flow rate (Qmax) was (5.7±2.3) mL/s. Results The operations were completed successfully in all cases with a mean lithotripsy time of 38 min (16-58 minutes) and a mean TURP time of 65 min (40-100 minutes). No complications occurred during the operation. Urethral catheter was withdrawn 5-8 days after operation, with a mean period of 6.5 days. Four patients had anterior urethral stricture after operation, but recovered through treatment. Fifty-four patients were followed up for 2 to 6 months with an average follow-up time of 3 months. Two months after the operations, IPSS decreased to 7.8±1.6; Qmax increased to (18.5±4.1) mL/s; RU decreased to (16±22) mL and QOL was 2.5±0.3. Compared with preoperative conditions, the differences were all statistically significant (P＜0. 01). Conclusion Transurethral lithotripsy combined with TURP is an effective, safe and economical treatment for benign prostatic hyperplasia with bladder calculi.
Objective To evaluate the safety of Rongbisu capsule used for treating benign prostatic hyperplasia. Methods A total of 218 patients (average age 63.73±7.50 years old) with phase Ⅰor Ⅱ benign prostatic hyperplasia were treated with oral Rongbisu capsule at a dose of 3 granules twice daily. The therapeutic course was 6 weeks and hepatic function was determined every 2 weeks. Results The median value of ALT in 218 patients rose significantly after the patients took Rongbishu capsule for 6 weeks (P=0.001 7). There were 17 patients whose ALT level rose from normal to abnormal, the incidence was 7.80%. There were 3 patients whose hepatic function was seriously impaired (ALT＞200 IU/L). Conclusions The essential component of Rongbishu capsule is edible tulip which has been recorded in the medical literature as being toxic. Airpotato yam of which the alias is also edible tulip is easily mistaken for edible tulip. Airpotato yam is the tuber of dioscorea bulbifera L. (family dioscoreaceae) which has confirmed hepatotoxcity. Our study result indicates that in order to insure the safety of Chinese crude drug, the origin of Chinese crude drug should be defined in the formulation according to the standard of Chinese drugs preparation. Pharmaceutical enterprises should strictly abide by the standards to identify the origin of Chinese crude drugs when approving the raw materials, especially for species which are poisonous and easily mistaken.
Objective Evidence-based medicine was used to make an individualized treatment plan for newly diagnosed prostatic hyperplasia in an elderly patient. Methods After clinical problems were discovered, evidence was collected from CBM, CNKI, The Cochrane Library, PubMed, EMBASE, ScienceDirect, Springer, and ProQuest databases according to our predefined search strategy. The search was done through 2008. The internal and external validity of the evidence was assessed. The evidence, combined with the patient value, was applied to the patient. Results A total of 39 systematic reviews involving 137 randomized controlled trials were identified. A rational treatment plan was made upon a critical evaluation of the data. After one year follow-up, the treatment protocol was proven correct. Conclusion The treatment efficacy in newly diagnosed prostatic hyperplasia in the elderly has been improved by determining an individualized treatment protocol according to evidence-based methods.
【摘要】 目的 探討經尿道等離子雙極電切術（PKRP）治療前列腺增生的安全性及臨床療效。 方法 2009年2-12月，采用PKRP治療前列腺增生患者76例，記錄手術時間、手術療效及術后并發癥。 結果 患者手術時間35～130 min，平均55 min。術中失血60～150 mL，均未輸血。手術切除前列腺質量18～72 g。無直腸和膀胱穿孔，無電切綜合征（TURS）及閉孔神經反射發生，無一例發生真性尿失禁，無死亡。術后隨訪2～6個月，IPSS評分平均為9分，最大尿流率平均為16.7 mL/s。 結論 PKRP是治療前列腺增生的理想方法之一。【Abstract】 Objective To evaluate the efficacy of transurethral plasmakinetic resection of the prostate (PKRP) on benign prostatic hyperplasia. Methods A total of 76 patients with benign prostatic hyperplasia from February to December 2009 were treated with PKRP. The operative duration, therapeutic effect and postoperative complications were observed and recorded. Results The operative duration ranged from 35 to 130 minutes (average 55 minutes).The intraoperative blood loss was 60-150 mL, and no one needed transfusion.The prostate gland excised weight was 18-72 g. There were no intestinal and bladder perforation, no transurethral resection syndrome (TURS) or obturator nerve reflex occurs, and no urinary incontinence or death.IPSS score was nine and the maximal average uroflow was 16.7 mL/s during the 2-6 month follow-up. Conclusion PKRP is one of the ideal methods treating benign prostatic hyperplasia, especially for high-risk patients with benign prostatic hyperplasia.
